Spartan’s bedside DNA test is a major advancement in medicine.
-Ahmed Abdel-Hamid, Managing Director of DELTA
Ottawa, Ontario (PRWEB) May 24, 2012
Spartan Bioscience today announced exclusive agreements with DELTA Trading & Development for distribution of the first bedside DNA test in the Middle East. The agreements cover Bahrain, Egypt, Kuwait, Oman, Qatar, Saudi Arabia, Sudan, and United Arab Emirates. DELTA specializes in the distribution of life science products, and will concentrate its efforts on reaching cardiologists in hospitals and other medical centers.
The Spartan RX CYP2C19 is the first bedside DNA test in medicine.(1) It identifies carriers of the CYP2C19*2 gene, which is carried by approximately 30% of the world’s population.(2) Genetic carriers who receive Plavix® (clopidogrel) following a cardiac stent have a 42 percent higher risk of death, stroke, or heart attack in the first year compared to non-carriers.(3) Following this stenting procedure, patients are typically prescribed clopidogrel for one year or more. In 2009, Plavix® was the second best-selling drug in the world, with over $9 billion in revenues.
“DELTA has 13 years of experience in distributing innovative life science products,” said Larry D’Andrea, CEO of Spartan Bioscience. “DELTA is the ideal partner for bringing Spartan’s bedside DNA test to doctors and hospitals in the Middle East.”
“Spartan’s bedside DNA test is a major advancement in medicine. For the first time, doctors can get genetic results at the time of cardiac stenting,” said Ahmed Abdel-Hamid, Managing Director of DELTA. “At the 2012 World Congress of Cardiology conference in Dubai, we received a tremendous amount of interest from cardiologists for this cutting-edge technology.”
About the Spartan RX CYP2C19
The Spartan RX CYP2C19 is the first bedside DNA test in medicine.(1) It identifies carriers of the CYP2C19*2 gene in 1 hour. This gene is carried by approximately 30 percent of the world’s population.(2) Genetic carriers who receive Plavix® following a cardiac stent insertion to open clogged arteries have a 42 percent higher risk of death, stroke, or heart attack in the first year compared to non-carriers.(3) Currently, genetic testing is performed in central labs and it takes up to seven days to get a test result back. A rapid test is needed because most of the complications for CYP2C19 carriers occur in the first 24 to 48 hours.(3,4) In March 2010, the FDA issued a warning for Plavix regarding CYP2C19 poor metabolizers. The Spartan RX CYP2C19 has CE IVD Mark regulatory approval for Europe and other countries recognizing the CE IVD Mark. Spartan Bioscience is working towards FDA 510(k) clearance in the United States. For more information, please visit our website at: http://www.spartanbio.com/products/spartan-rx
About Spartan Bioscience
Spartan Bioscience is the leader in point-of-care DNA testing. The Spartan RX is the first complete sample-to-result, point-of-care DNA testing system in medicine. It is a fully integrated DNA collection, extraction and analysis platform, with an intuitive interface that is easy to operate—no laboratory training required. For the first time, healthcare providers and their patients can get DNA results on demand. For more information, please visit our website at: http://www.spartanbio.com.
The Spartan logo is a registered trademark of Spartan Bioscience Inc.
Plavix is a registered trademark of Bristol-Myers Squibb/Sanofi Pharmaceuticals.
1. Roberts JD et al. (2012). Lancet. 379:1705–11.
2. Damani SB, Topol EJ. (2010). J Am Coll Cardiol. 56:109–11.
3. Mega JL et al. (2009). N Engl J Med. 360:354–62.
4. Wiviott SD et al. (2007). N Engl J Med. 357:2001–15.